Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01263769 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
A Phase 2 study of Kidney Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT01263769: Completed Phase 2 study of Kidney Cancer, sponsored by M.D. Anderson Cancer Center.
NCT01263769 is a Phase 2 study of Kidney Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 39 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01263769, a Phase 2 study of Kidney Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if axitinib can help to control kidney cancer. The safety of this drug will also be studied.
Conditions Studied
Interventions
- DRUG Axitinib
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2011-02 |
| Est. Completion | 2023-06-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01263769
The ClinicalTrials.gov registry entry for NCT01263769 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (96% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 1 intervention - of which Axitinib is the first listed.
NCT01263769 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01263769 about?
NCT01263769 is a clinical study titled "Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)". The goal of this clinical research study is to learn if axitinib can help to control kidney cancer. The safety of this drug will also be studied.
What is the current status of trial NCT01263769?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2011-02. Estimated completion is 2023-06-05.
What conditions does trial NCT01263769 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT01263769?
The interventions under investigation include: Axitinib (DRUG).
Who is sponsoring clinical trial NCT01263769?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01263769 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.